In the claims:

Please amend the claims as follows:

1-18. (cancelled).

19. (withdrawn). A chimeric receptor containing two or more independent polypeptide chains, each of said chains comprising in N- to C-terminus sequence:

(1) an extracellular ligand association domain;
(2) a spacer domain;
(3) a transmembrane domain; and
(4) one or more intracellular domains; provided that at least two of said domains in one chain are not naturally fused to each other, and wherein the spacer and/or transmembrane domains are selected to remain unassociated except in the presence of bound ligand.

20. (withdrawn). A chimeric receptor according to Claim 19 wherein each extracellular ligand association domain is an antibody variable region (V_H or V_L) domain, a T-cell receptor variable region domain (TCRα, TCRβ, TCRγ, TCRδ), CD8α, CD8β, CD11a, CD11b, CD11c, CD18, CD29, CD49a, CD49b, CD49c, CD49d, CD49e, CD49f, CD61, CD41 or CD51 chain or a fragment thereof.

21. (withdrawn). A chimeric receptor according to Claim 20 wherein each association domain is structurally different to each other.

22. (withdrawn). A chimeric receptor according to Claim 19 wherein the ligand association domains of the chimeric receptor are a V_H domain paired with a V_L domain, two or more TCRα, TCRβ, TCFγ, and/or TCRδ domains, a CD8α or β homo- or heterodimer, CD18 paired with one or more of CD11a, b, or c, CD29 paired with one or more of CD49a, b, c, d, e, or f, and CD61 paired with CD41c and/or CD51.

23. (withdrawn). A chimeric receptor according to Claim 19 wherein each intracellular domain is a naturally occurring polypeptide signaling sequence.

24. (withdrawn). A chimeric receptor according to Claim 23 wherein each signaling sequence is all or part of the zeta, eta or epsilon chain derived from the T-cell receptor; CD28; CD4; CD8; the γ chain of an Fc receptor; a signaling component from a cytokine receptor, a colony stimulating factor receptor, a tyrosine kinase and binding domains thereof; or an adhesion molecule.

25. (withdrawn). A chimeric receptor according to Claim 19 wherein the transmembrane domain is an oligo- or polypeptide derived from all or part of the alpha, beta or zeta chain of the T-cell receptor, CD28, CD8, CD4, CD3ϵ, CD45 and members of the tetraspan family, a cytokine receptor, or a colony stimulating factor receptor.

26. (withdrawn). A chimeric receptor according to Claim 19 wherein each spacer domain is a polypeptide comprising 20 to 100 amino acids.

27. (withdrawn). A chimeric receptor according to Claim 19 wherein each independent polypeptide chain has a secretion signal sequence attached to the N-terminus of the association domain of each chain.

28. (withdrawn). A chimeric receptor according to Claim19 wherein the chimeric receptor has two independent polypeptide chains.

29. (withdrawn). A chimeric receptor according to Claim 28 wherein one polypeptide chain has a ligand association domain which is a V_H domain or a fragment thereof, and the other has a ligand association domain which is a V_L domain or a fragment thereof.

30. (withdrawn). A chimeric receptor of Claim 19, wherein the spacer domain is modified to remain unassociated except in the presence of bound ligand.

31. (withdrawn). A chimeric receptor of Claim 19, wherein the transmembrane domain is modified to remain unassociated except in the presence of bound ligand.

32. (withdrawn). A chimeric receptor of Claim 19, wherein the spacer domain is a CD8 domain.

33. (withdrawn). A chimeric receptor of Claim 32, wherein the CD8 spacer domain is a modified CD8 spacer domain.

34. (currently amended). A nucleic acid sequence encoding a chimeric receptor, wherein the chimeric receptor contains two independent polypeptide chains, a first polypeptide chain and a second polypeptide chain, wherein the first polypeptide chain comprises in N- to C-terminus sequence:

(1) an extracellular ligand association domain of an antibody heavy chain variable region;
(2) a spacer domain of any polypeptide comprising 20 to 100 amino acid residues;
(3) a transmembrane domain of any oligopeptide ~~oligonucleotide~~ or polypeptide derived from all or part of a human CD4 transmembrane domain; and

an intracellular domain, wherein the intracellular domain is a signaling domain comprised of any naturally occurring polypeptide signaling sequence that is all or part of the human CD4 intracellular signaling domain;

and wherein the second polypeptide chain comprises in N- to C-terminus sequence:

(4) an extracellular ligand association domain of an antibody light chain variable region;
(5) a spacer domain of any polypeptide comprising 20 to 100 amino acid residues;
(6) a transmembrane domain of any oligopeptide ~~oligonucleotide~~ or polypeptide derived from all or part of a human CD4 transmembrane domain; and

an intracellular domain, wherein the intracellular domain is a signaling domain comprised of any naturally occurring polypeptide signaling sequence that is all or part of the human T cell receptor zeta chain;

wherein the spacer and/or transmembrane domains of the first and second polypeptide chains are selected to remain unassociated except in the presence of bound ligand.

35. (previously presented). A nucleic acid sequence according to Claim 34 in association with a carrier.

36. (withdrawn). A nucleic acid sequence according to Claim 35 wherein the carrier is a viral vector, a liposomal vector, a cationic lipid or an antibody.

37. (withdrawn). A nucleic acid sequence according to Claim 35 wherein the carrier is a targeted carrier.

38. (previously presented). A nucleic acid sequence according to Claim 34 wherein the nucleic acid sequence is on a plasmid.

39. (canceled).

40. (withdrawn). An effector cell containing a nucleic acid sequence or a plasmid according to Claim 34.

41. (withdrawn). An effector cell expressing a chimeric receptor of Claim 19.